Publication | Closed Access

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Tamoxifen TreatmentClinical EffectivenessMedicineClinical TrialsBreast CancerPharmacotherapyIntergroup Exemestane StudyDrug TrialOncologyExemestane Versus TamoxifenAnesthesiology